Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Common Equity: 2023-2025

Historic Common Equity for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $231.1 million.

  • Tonix Pharmaceuticals Holding's Common Equity rose 211.47% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.1 million, marking a year-over-year increase of 211.47%. This contributed to the annual value of $139.6 million for FY2024, which is 32.25% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Common Equity stood at $231.1 million for Q3 2025, which was up 37.58% from $168.0 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Common Equity peaked at $231.1 million during Q3 2025, and registered a low of $42.1 million during Q2 2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Common Equity had a median value of $139.6 million in 2024 and averaged $134.2 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 70.03% in 2024, then spiked by 299.02% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Common Equity stood at $105.5 million in 2023, then soared by 32.25% to $139.6 million in 2024, then skyrocketed by 211.47% to $231.1 million in 2025.
  • Its last three reported values are $231.1 million in Q3 2025, $168.0 million for Q2 2025, and $180.4 million during Q1 2025.